Why the next health care fight will be over the high price of care
Real-time health care pricing is not a big ask and we cannot tolerate unexpected medical billing any longer.
Trump's $200 prescription cards won't hit mailboxes just yet
Government officials said Friday that key details of Trump's election-year giveaway still have to be fleshed out
How a new Supreme Court justice could change heath care
Jan Dubauskas on future of heath care
Trump's new health care initiative 'fairly limited': Mulvaney
Former Acting White House Chief of Staff Mick Mulvaney said on Friday that legislation is needed to "dramatically" change U.S. health care.
Blue Cross Blue Shield strikes $2.7B tentative antitrust settlement
The insurance giant is accused of practices that allegedly limited competition.
AstraZeneca waiting for FDA to greenlight restart of US drug trial
AstraZeneca says it's still waiting on federal approval to resume the U.S. clinical trial of its COVID-19 vaccine candidate nearly three weeks after the study was halted over safety concerns.
GoodRx co-CEO: Aiming to make health care purchases simple
GoodRx co-CEO on going public
Johnson & Johnson's COVID-19 candidate enters third trial phase
J&J is making innovative strides with Phase 3 trials of a single-shot COVID-19 vaccine.
GoodRx sells shares above target in latest U.S. IPO success
GoodRx Holdings Inc on Tuesday priced its initial public offering higher than anticpated
Walmart to test drone delivery of COVID-19 test kits
The U.S. retailer has partnered with Quest Diagnostics and drone services provider DroneUp, to test-deliver collection kits in north Las Vegas from Tuesday and plans to conduct a trial run in Cheektowaga, New York in early October.
Medicare may not cover coronavirus vaccine costs: report
The program does not cover drugs approved for emergency use.
Biden to focus on health care in Supreme Court debate
Democratic presidential nominee Joe Biden used the sudden Supreme Court vacancy to reinforce his argument that the upcoming election should be a referendum on President Donald Trump's handling of health care and the coronavirus.
Roche arthritis drug reduces likelihood COVID-19 patients will need ventilator, company claims
Patients who received the drugs were 44% less likely to progress to the point where they would need to rely on ventilation.
Pfizer vaccine bets on early win vs coronavirus, documents show
Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run.
Johnson & Johnson charged in lawsuit by New York for alleged role in opioid crisis
New York State has filed civil charges against Johnson & Johnson and its Janssen Pharmaceuticals subsidiaries on insurance fraud for minimizing the risks of opioid treatment and targeting the most vulnerable population.
New coronavirus antibody treatment by Eli-Lilly reduces need for hospitalization: study
Eli Lilly CEO David Ricks told FOX Business on Wednesday that the results of a mid-stage clinical trial assessing the drugmaker's experimental antibody treatment reduced the rate of hospitalization in COVID-19 patients.
Coronavirus vaccine study by Pfizer shows mild-to-moderate side effects
Pfizer Inc said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
AstraZeneca COVID-19 trial on hold in US as FDA investigates UK participant's serious illness
“We don’t have all facts, so we don’t know the causation per se of this, but we really need to look into it," FDA Commissioner Stephen Hahn said.
Company behind New York, Boston Sports Clubs files for bankruptcy protection
The company that runs New York Sports Club and Lucille Roberts gyms filed for bankruptcy protection on Monday, as business and memberships decline at gyms in parts of the nation still grapple with the novel coronavirus pandemic.
Gilead to buy Immunomedics in $21B deal
Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.



















